FIM
PTGX icon

Freedom Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Freedom Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,867
Closed -$212K – 649
2020
Q3 		$212K Sell
10,867
-2,322
-18% -$43.6K 0.02% 494
2020
Q2 		$233K Sell
13,189
-3,933
-23% -$49.3K 0.03% 472
2020
Q1 		$141K Buy
17,122
+175
+1% +$1.31K 0.01% 636
2019
Q4 		$119K Sell
16,947
-1,564
-8% -$15.5K 0.01% 641
2019
Q3 		$222K Sell
18,511
-1,733
-9% -$21.8K 0.02% 606
2019
Q2 		$245K Sell
20,244
-355
-2% -$3.92K 0.02% 579
2019
Q1 		$259K Sell
20,599
-5,736
-22% -$50.6K 0.02% 560
2018
Q4 		$177K Sell
26,335
-10,964
-29% -$87K 0.01% 710
2018
Q3 		$355K Buy
37,299
+2,166
+6% +$18.6K 0.02% 655
2018
Q2 		$236K Buy
+35,133
New +$270K 0.01% 836

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Freedom Investment Management's PTGX Position: Q4 2020 in Review

Freedom Investment Management sold out of Protagonist Therapeutics (PTGX) in Q4 2020, closing a stake of 10,867 shares — an estimated $212K sold.

Freedom Investment Management first reported a position in PTGX in Q2 2018 and held it in 10 quarters. The position peaked at $355K in Q3 2018. 128 funds tracked by Wall St. Rank hold PTGX as of Q4 2020.

  • Freedom Investment Management reported no remaining Protagonist Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Freedom Investment Management sold 10,867 Protagonist Therapeutics shares in Q4 2020, an estimated $212K.
  • Freedom Investment Management first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 10 quarters.
  • Freedom Investment Management's Protagonist Therapeutics position peaked at $355K in Q3 2018.
  • 128 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2020.

Based on Freedom Investment Management's 13F filing for Q4 2020, filed 11 Feb 2021.